Anthony M. Liang

Array ( [id] => 20402286 [patent_doc_number] => 12492255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Anti-TREM2 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 19/217020 [patent_app_country] => US [patent_app_date] => 2025-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 59 [patent_no_of_words] => 56310 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19217020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19724079 [patent_doc_number] => 20250026830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => BINDING AGENTS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/907087 [patent_app_country] => US [patent_app_date] => 2024-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18907087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543183 [patent_doc_number] => 20240360219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => CD47/PD-L1-TARGETING PROTEIN COMPLEX AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/769347 [patent_app_country] => US [patent_app_date] => 2024-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18769347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916212 [patent_doc_number] => 12291565 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Tau binding compounds [patent_app_type] => utility [patent_app_number] => 18/734892 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 95044 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111236 [patent_doc_number] => 20240122986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/543191 [patent_app_country] => US [patent_app_date] => 2023-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140522 [patent_doc_number] => 20240139314 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/486563 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034227 [patent_doc_number] => 20240084042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/464580 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20701404 [patent_doc_number] => 12624104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => Compositions and methods for treating cancer with anti-CD19 immunotherapy [patent_app_type] => utility [patent_app_number] => 18/330587 [patent_app_country] => US [patent_app_date] => 2023-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 27102 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18330587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842740 [patent_doc_number] => 20230405144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => INDUCIBLE CELL DEATH SYSTEMS [patent_app_type] => utility [patent_app_number] => 18/199154 [patent_app_country] => US [patent_app_date] => 2023-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18199154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300081 [patent_doc_number] => 20240228650 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => CD3/BCMA/CD38 Trispecific Antibodies [patent_app_type] => utility [patent_app_number] => 18/312519 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300081 [patent_doc_number] => 20240228650 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => CD3/BCMA/CD38 Trispecific Antibodies [patent_app_type] => utility [patent_app_number] => 18/312519 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19990941 [patent_doc_number] => 20250129163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/264242 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 1028 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628288 [patent_doc_number] => 20230287146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => BISPECIFIC GPC3xCD28 AND GPC3xCD3 ANTIBODIES AND THEIR COMBINATION FOR TARGETED KILLING OF GPC3 POSITIVE MALIGNANT CELLS [patent_app_type] => utility [patent_app_number] => 18/183840 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808914 [patent_doc_number] => 20230383249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => ALLOGENEIC THERAPEUTIC CELLS [patent_app_type] => utility [patent_app_number] => 18/175049 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987817 [patent_doc_number] => 20240059786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => ANTI-CD28 X ANTI-TROP2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/174370 [patent_app_country] => US [patent_app_date] => 2023-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18174370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597323 [patent_doc_number] => 20230272118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Dosing Regimens for Mitigation of Cytokine Release Syndrome [patent_app_type] => utility [patent_app_number] => 18/114057 [patent_app_country] => US [patent_app_date] => 2023-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -117 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18114057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18710487 [patent_doc_number] => 20230333112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => METHODS OF DETECTING TRBC1 OR TRBC2 [patent_app_type] => utility [patent_app_number] => 18/174246 [patent_app_country] => US [patent_app_date] => 2023-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 122260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18174246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451585 [patent_doc_number] => 20230192863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/167438 [patent_app_country] => US [patent_app_date] => 2023-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18167438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511412 [patent_doc_number] => 20230227561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => ANTI-CANINE CD16 POLYPEPTIDES, ANTI-CANINE CD64 POLYPEPTIDES, COMPOSITIONS INCLUDING SAME, AND METHODS OF USING [patent_app_type] => utility [patent_app_number] => 18/099448 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18099448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987829 [patent_doc_number] => 20240059798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => CONDITIONALLY ACTIVATED ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/069529 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 130233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069529 [rel_patent_id] =>[rel_patent_doc_number] =>)